Efficacy and Safety of Rebamipide versus Its New Formulation, AD-203, in Patients with Erosive Gastritis: A Randomized, Double-Blind, Active Control, Noninferiority, Multicenter, Phase 3 Study

BACKGROUND/AIMS: The mucoprotective drug rebamipide is used to treat gastritis and peptic ulcers. We compared the efficacy of Mucosta(Ⓡ) (rebamipide 100 mg) and its new formulation, AD-203 (rebamipide 150 mg), in treating erosive gastritis. METHODS: This double-blind, active control, noninferiority,...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Gwang Ha, Lee, Hang Lak, Joo, Moon Kyung, Park, Hong Jun, Jung, Sung Woo, Lee, Ok-Jae, Kim, Hyungkil, Chun, Hoon Jai, Lee, Soo Teik, Kim, Ji Won, Jeon, Han Ho, Chung, Il-Kwun, Kim, Hyun-Soo, Lee, Dong Ho, Kim, Kyoung-Oh, Lim, Yun Jeong, Park, Seun-Ja, Cho, Soo-Jeong, Kim, Byung-Wook, Ko, Kwang Hyun, Jeon, Seong Woo, Kim, Jae Gyu, Sung, In-Kyung, Kim, Tae Nyeun, Sung, Jae Kyu, Park, Jong-Jae
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Editorial Office of Gut and Liver 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8593495/
https://www.ncbi.nlm.nih.gov/pubmed/33827990
http://dx.doi.org/10.5009/gnl20338

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8593495/
https://www.ncbi.nlm.nih.gov/pubmed/33827990
http://dx.doi.org/10.5009/gnl20338

Ejemplares similares